IP Library › Granted Patent US 12,012,598
Granted Patent B2
US 12,012,598 · App. 16/324,955 · Granted Jun 18, 2024

Manipulated immunoregulatory element and immunity altered thereby

Inventors: Seok Joong Kim (Seoul, KR); Yoon-Young Kim (Seoul, KR); Ho-Sung Yu (Gyeonggi-do, KR); In-Young Jung (Gyeonggi-do, KR); Jung Min Lee (Seoul, KR)
Assignee: TOOLGEN INCORPORATED
C12N15/1132A61K35/14C07K14/70503C07K14/70564C07K14/70575C07K14/70578C07K14/70596C12N5/0637C12N5/0638C12N5/064C12N5/0646C12N15/102C12N15/1138C12N15/52C12N15/63C12N15/85C12N9/22C12N2310/20C12N2320/30Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,012,598
App. No.
16/324,955
Granted
Jun 18, 2024
Kind
B2
Abstract

The present invention relates to an artificially manipulated immune system having an improved immune effect. More particularly, the present invention relates to an immune system having functions artificially altered which comprises artificially manipulated immunoregulatory elements and cells containing the same. Contemplated according to a particular embodiment is an immune system comprising artificially manipulated immunoregulatory genes such as PD-1, CTLA-4, A20, DGKα, DGKζ, FAS, EGR2, PPP2R2D, PSGL-1, KDM6A, and TET2, and/or expression products thereof.

Claims (16)

1. A composition for the production of an artificially engineered immune cell comprising any one or more of an artificially engineered Dgkα gene and an artificially engineered Dgkζ gene,

wherein the composition comprises:

(i) a Cas9 protein derived from Streptococcus pyogenes , or a nucleic acid encoding the Cas9 protein derived from S. pyogenes ; and

(ii) a guide RNA or a nucleic acid encoding the guide RNA, wherein the guide RNA is at least one selected from a first guide RNA and a second guide RNA,

wherein the first guide RNA comprises a first guide sequence which consists of the 1 st to 20 th nucleotides of SEQ ID NO: 23, in which each thymine of the first guide sequence are changed to uracil,

wherein the second guide RNA comprises a second guide sequence which consists of the 1 st to 20 th nucleotides of SEQ ID NO: 113, in which each thymine of the second guide sequence are changed to uracil, and

wherein the first guide RNA and the Cas9 protein are capable of forming a first RNA-protein complex which is capable of manipulating the Dgkα gene, and wherein the second guide RNA and the Cas9 protein are capable of forming a second RNA-protein complex which is capable of manipulating the Dgkζ gene.

2. The composition of claim 1 , wherein the composition comprises:

(i) the first guide RNA or the nucleic acid encoding the first guide RNA; and

(ii) the Cas9 protein or the nucleic acid encoding the Cas9 protein.

3. The composition of claim 1 , wherein the composition comprises:

(i) the second guide RNA or the nucleic acid encoding the second guide RNA; and

(ii) the Cas9 protein or the nucleic acid encoding the Cas9 protein.

4. The composition of claim 1 , wherein the composition comprises:

(i) the first guide RNA or the nucleic acid encoding the first guide RNA and the second guide RNA or the nucleic acid encoding the second guide RNA; and

(ii) the Cas9 protein or the nucleic acid encoding the Cas9 protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2019
From: KIM, SEOK JOONG; KIM, YOON-YOUNG; YU, HO-SUNG; JUNG, IN-YOUNG; LEE, JUNG MIN
To: TOOLGEN INCORPORATED
Reel/Frame 048305/0967 →
Priority Claims (1)
KR 10-2016-0103308 · Aug 12, 2016 · national
Continuity (2)
Provisional Application 62502822 · May 8, 2017
Related Publication 20190185860A1 · Jun 20, 2019